Evaluation of the phencyclidine-like discriminative stimulus effects of novel NMDA channel blockers in rats

Psychopharmacology

Volumn 170, Issue 2, 2003, Pages 215-224

  Nicholson, Katherine L ^a   Balster, Robert L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug discrimination; NMDA receptor antagonists; Phencyclidine; Rats; Side effects

Indexed keywords

1 (4 METHOXYPHENYL) 1,2,3,4 TETRAHYDROISOQUINOLINE; 1 METHYL 1 PHENYL 1,2,3,4 TETRAHYDROISOQUINOLINE; 1 PHENYL 1,2,3,4 TETRAHYDROISOQUINOLINE; 8 (2 METHOXYPHENYL) 1,2,3,4 TETRAHYDROISOQUINOLINE; ALAPROCLATE; ANTAZOLINE; FR 115427; IDAZOXAN; N METHYL 1,3 DIPHENYLISOPROPYLAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NERAMEXANE; ORPHENADRINE; PD 137889; PD 138289; PHENCYCLIDINE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BINDING SITE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CORRELATION ANALYSIS; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG DISCRIMINATION; DRUG POTENCY; DRUG SELECTIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RECEPTOR BLOCKING; REINFORCEMENT; STIMULUS RESPONSE;

ANIMALS; DISCRIMINATION (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; EXCITATORY AMINO ACID ANTAGONISTS; MALE; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; REINFORCEMENT (PSYCHOLOGY); REINFORCEMENT SCHEDULE; TETRAHYDROISOQUINOLINES;

EID: 0242492184     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-003-1527-6     Document Type: Article

References (68)

1. Balster RL (1989) Substitution and antagonism in rats trained to discriminate (+)-N-allylnormetazocine from saline. J Pharmacol Ther 249:749-756
2. Balster RL (1991a) Discriminative stimulus properties of phencyclidine and other NMDA antagonists. In: Glennon RA, Järbe TUC, Frankenheim J (eds) Drug discrimination: applications to drug abuse research. National Institute on Drug Abuse Research Monograph Series 116, DHHS Publication No. ADXM 92-1878. U.S. Government Printing Office, Washington, pp 163-180
3. Balster RL (1991b) Drug abuse potential evaluation in animals. Br J Addict 86:549-1558
4. Balster RL, Willetts J (1996) Phencyclidine: a drug of abuse and a tool for neuroscience research. In: Schuster CR, Kuhar MJ (eds) Pharmacological aspects of drug dependence: towards an integrated neurobehavioral approach. Handbook of experimental pharmacology, vol 118. Springer, Berlin Heidelberg New York, pp 233-262
5. Beardsley PM, Hayes BA, Balster RL (1990) The self-administration of MK-801 can depend upon drug-reinforcement history and its discriminative stimulus properties are phencyclidine-like in rhesus monkeys. J Pharmacol Ther 252:953-959
6. Bigge CF, Johnson G, Hays SJ, Malone TC, Ortwine DF, Boxer PA, Marcoux FW, Coughenour LL (1992) Development of polycyclic amines as potent noncompetitive NMDA antagonists. In: Kamenka J-M, Domino EF (eds) Multiple sigma and PCP receptor ligands: mechanisms for neuromodulation and neuroprotection? NPP Books, Ann Arbor, pp 1-20
7. Bigge CF, Malone TC, Hays SJ, Johnson G, Novak PM, Lescosky LJ, Retz DM, Ortwine DF, Probert AW Jr, Coughenour LL, Boxer PA, Robichaud LJ, Brahce LJ, Shillis JL (1993) Synthesis and pharmacological evaluation of a 4α-phenanthrenamine derivatives acting at the phencyclidine binding site of the N-methyl-D-aspartate receptor. J Med Chem 36:1977-1995
8. Bliss CI (1967) Statistics in biology. McGraw-Hill, New York
9. Brady KT, Balster RL, May EL (1982a) Stereoisomers of N-allylnormetazocine: phencyclidine-like behavioral effects in squirrel monkeys and rats. Science 215:178-180
10. Brady KT, Woolverton WL, Balster RL (1982b) Discriminative stimulus and reinforcing properties of etoxadrol and dexoxadrol in monkeys. J Pharmacol Exp Ther 220:56-62
11. Doshay LJ, Constable K (1957) Treatment of paralysis agitans with orphenadrine (Disipal). Results in 176 cases. J Am Med Assoc 163:1352-1357
12. Finch JW (1959) Clinical trial of orphenadrine in skeletal muscle disorders. Clin Med Surg 6:195-198
13. Frost SJ, Eccleston D, Marshall EF, Hassanyeh F (1984) Alaproclate: an open clinical study in depressive illness. Psychopharmacology 83:285-287
14. Geter-Douglass B, Witkin JM (1999) Behavioral effects and anticonvulsant efficacies of low-affinity, uncompetitive NMDA antagonists in mice. Psychopharmacology 146:280-289
15. Grant KA, Colombo G, Grant J, Rogawski MA (1996) Dizocilpine-like discriminative stimulus effects of low-affinity uncompetitive NMDA antagonists. Neuropharmacology 35:1709-1719
16. Gray NM, Cheng BK, Mick SJ, Lair CM, Contrereas PC (1989) Phencyclidine-like effects of tetrahydroisoquinolines and related compounds. J Med Chem 32:1242-1248
17. Hays SJ, Novak PM, Ortwine DF, Bigge CF, Colbry NL, Johnson G, Lescosky LJ, Malone TC, Michael A, Reily MD, Coughenour LL, Brahce LJ, Shillis JL, Probert A Jr (1993) Synthesis and pharmacological evaluation of hexahydrofluorenamines as noncompetitive antagonists at the N-methyl-D- aspartate receptor. J Med Chem 36:654-670
18. Heresco-Levy U, Javitt DC (1998) The role of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes. Eur Neuropsychopharmacol 8:141-152
19. Hesselink MB, Parsons CG, Wollenburg C, Danysz W (1999) Brain distribution of an uncompetitive NMDA receptor antagonist: comparison to its in vitro potency in electrophysiological studies. Naunyn Schmiedebergs Arch Pharmacol 360:144-550
20. Hoddes SH (1964) Orphenadrine citrate in the treatment of muscular pain. Practitioner 193:76-80
21. Hodgkiss JP, Sherriffs HJ, Cottrell DA, Shirakawa K, Kelly JS, Kuno A, Ohkubo M, Butcher SP, Olverman HJ (1993) Neurochemical and electrophysiological studies on FR 115427, a novel non-competitive NMDA receptor antagonist. Eur J Pharmacol 240:219-227
22. Holtzman SG (1990) Discriminative stimulus effects of drugs: relationship to potential for abuse. In: Adler MA, Cowan A (eds) Testing and evaluation of drugs of abuse. Wiley-Liss, New York, pp 193-210
23. Hu P-S, Ross SB (1997) NMDA receptor-mediated increase in cyclic GMP in the rat cerebellum in vivo is blocked by alaproclate and GEA-857. Pharmacol Tox 80:97-102
24. Hunskaar S, Donnell D (1991) Clinical and pharmacological review of the efficacy of orphenadrine and its combination with paracetamol in painful conditions. J Int Med Res 19:71-87
25. Jackson A, Sanger DJ (1988) Is the discriminative stimulus produced by phencyclidine due to an interaction with N-methyl-D-aspartate receptors? Psychopharmacology 96:87-92
26. Jones HE, Li H, Balster RL (1998) Failure of ibogaine to produce phencyclidine-like discriminative stimulus effects in rats and monkeys. Pharmacol Biochem Behav 59:413-418
27. 2 site ligand 2-BFI. J Psychopharmacol 10:273-278
28. Katsuta K, Nakanishi H, Shirakawa K, Yoshida K, Takagi K, Tamura A (1995) The neuroprotective effect of the novel noncompetitive NMDA antagonist, FR 115427 in focal cerebral ischemia in rats. J Cereb Blood Flow Metab 15:345-348
29. Kleven MS, Koek W (1998) Discriminative stimulus effects of 8-hydroxy-2-(di-n-propylamino)tetralin in pigeons and rats: species similarities and differences. J Pharmacol Exp Ther 284:238-249
30. Kolasa K, Kleinrok Z, Rajtar G, Juszkiewicz M (1984) Effects of histamine and H1-and H2-receptor antagonists on wet-dog-shake episodes in rats induced with tranylcypromine and 5-methoxytryptamine. Acta Physiol Pol 35:225-230
31. Kornhuber J, Parsons CG, Hartmann S, Retz W, Kamolz S, Thome J, Riederer P (1995) Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J Neural Trans 102:237-246
32. 3H-PCP binding potency measured autoradiographically. Pharmacol Biochem Behav 25:1051-1058
33. Lindberg UH, Thorberg SO, Bengtsson S, Renyi AL, Ross SB, Ogren SO (1978) Inhibitors of neuronal monoamine uptake. 2. Selective inhibition of 5-hydroxytryptamine uptake by alpha-amino acid esters of phenethyl alcohols. J Med Chem 21:448-456
34. Liu Y, Belayev L, Zhao W, Busto R, Ginsberg MD (2000) MRZ 2/579, a novel uncompetitive N-methyl-D-aspartate antagonist, reduces infarct volume and brain swelling and improves neurological deficit after focal cerebral ischemia in rats. Brain Res 862:111-119
35. Marona-Lewicka D, Nichols DE (1998) Drug discrimination studies of the interoceptive cues produced by selective serotonin uptake inhibitors and selective serotonin releasing agents. Psychopharmacology 138:67-75
36. Millan MJ, Dekeyne A, Papp M, La Rochelle CD, MacSweeny C, Peglion J-L, Brocco M (2001) S33005, a novel ligand at both serotonin and norepinephrine transporters. II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther 298:581-591
37. Mindham RHS, Gaind R, Anstee BH, Rimmer L (1972) Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced Parkinsonism. Psychol Med 2:406-413
38. Moore KA, Lichtman AH, Poklis A, Borzelleca JF (1995) α-Benzyl-N-methylphenethylamine (BNMPA), an impurity of illicit methamphetamine synthesis: pharmacological evaluation and interaction with methamphetamine. Drug Alcohol Depend 39:83-89
39. Moore KA, Mirshahi T, Compton DR, Poklis A, Woodward JJ (1996) Pharmacological characterization of BNMPA (α-benzyl-N- methylphenethylamine), an impurity of illicit methamphetamine synthesis. Eur J Pharmacol 311:133-139
40. Nakanishi H, Katsuta K, Ueda Y, Takasugi H, Kuno A, Ohkubo M, Ogita K, Yoneda Y, Shirakawa K, Yoshida K (1995) Behavioral studies on FR 115427, a novel selective N-methyl-D-asparatate antagonist. Psychopharmacology 117:172-177
41. Nicholson KL, Jones HE, Balster RL (1998) Evaluation of the reinforcing and discriminative stimulus properties of the low-affinity N-methyl-D-aspartate channel blocker memantine. Behav Pharmacol 9:231-243
42. Nicholson KL, Hayes BA, Balster RL (1999) Evaluation of the reinforcing properties and phencyclidine-like discriminative stimulus effects of dextromethorphan and dextrorphan in rats and rhesus monkeys. Psychopharmacology 146:49-59
43. Noguchi S, Inukai T, Kuno T, Tanaka C (1992) The suppression of olfactory bulbectomy-induced muricide by antidepressants and antihistamines via histamine H1 receptor blocking. Physiol Behav 51:1123-1127
44. Ohkubo M, Kuno A, Katsuta K, Ueda Y, Shirakawa K, Nakanishi H, Nakanishi I, Kinoshita T, Takasugi H (1996) Studies on cerebral protective agents. IX. Synthesis of novel 1,2,3,4-tetrahydroisoquinolines as N-methyl-D-aspartate antagonists. Chem Pharmacol Bull 44:95-102
45. Olmos G, Ribera J, Garcia-Sevilla JA (1996) Imidazoli(di)ne compounds interact with the phencyclidine site of NMDA receptors in the rat brain. Eur J Pharmacol 310:273-276
46. Palmer GC (2001) Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies. Curr Drug Targets 2:241-271
47. Parsons CG, Quack G, Bresink I, Baran L, Przegalinski E, Kostowski W, Krzascik P, Hartmann S, Danysz W (1995) Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34:1239-1258
48. Parsons CG, Danysz W, Quack G (1998) Glutamate in CNS disorders as a target for drug development? Drug News Perspect 11:523-569
49. Parsons CG, Danysz W, Bartmann A, Spielmanns P, Frankiewicz T, Hesselink M, Eilbacher B, Quack G (1999) Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization. Neuropharmacology 38:85-108
50. Parsons CG, Danysz W, Quack G (2000) Memantine and the amino-alkyl-cyclohexane MRZ 2/579 are moderate affinity uncompetitive NMDA receptor antagonists - in vitro characterisation. Amino Acids 19:157-166
51. Popik P, Kozela E, Danysz W (2000) Clinically available NMDA receptor antagonists memantine and dextromethorphan reverse existing tolerance to the antinociceptive effects of morphine in mice. Naunyn Schmiedebergs Arch Pharmacol 361:425-432
52. Rogawski MA (1993) Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol Sci 14:325-331
53. Sanger DJ (1989) Discriminative stimulus effects of the alpha 2-adrenoceptor antagonist idazoxan. Psychopharmacology 99:117-121
54. Sanger DJ, Terry P, Katz JL (1992) Memantine has phencyclidine-like but not cocaine-like discriminative stimulus effects in rats. Behav Pharmacol 3:265-268
55. Shelton KL, Balster RL (1994) Ethanol drug discrimination in rats: substitution with GABA agonists and NMDA antagonists. Behav Pharmacol 5:441-451
56. 3H]FR 115427, a novel noncompetitive NMDA receptor antagonist, to rat brain membranes. Eur J Pharmacol 24:319-324
57. Slifer BL, Balster RL (1985) Phencyclidine-like discriminative stimulus properties of the stereoisomers of dioxadrol. Subst Alcohol Actions Misuse 5:273-280
58. Sukhotina IA, Bespalov AY (2000) Effects of the NMDA receptor channel blockers memantine and MRZ 2/579 on morphine withdrawal-facilitated aggression in mice. Psychopharmacology 149:345-350
59. 3H]-MK801 binding. Soc Neurosci Abstr 21:352
60. Svensson BE, Werkman TR, Rogawski MA (1994) Alaproclate effects on voltage-dependent K+ channels and NMDA receptors: studies in cultured rat hippocampal neurons and fibroblast cells transformed with Kv1.2 K+ channel cDNA. Neuropharmacology 33:795-804
61. Syvälahti EK, Kunelius R, Lauren L (1988) Effects of antiparkinsonian drugs on muscarinic receptor binding in rat brain, heart and lung. Pharmacol Toxicol 62:90-94
62. Wenk GL, Baker LM, Stoehr JD, Hauss-Wegrzyniak B, Danysz W (1998) Neuroprotection by novel antagonists at the NMDA receptor channel and glycineB sites. Eur J Pharmacol 347:183-187
63. Wilkinson A, Courtney M, Westlind-Danielsson A, Hallnemo G, Akerman KEO (1994) Alaproclate acts as a potent, reversible, noncompetitive antagonist of the NMDA receptor coupled ion flow. J Pharmacol Exp Ther 271:1314-1319
64. Willetts J, Balster RL (1988a) The discriminative stimulus effects of N-methyl-D-aspartate antagonists in phencyclidine-trained rats. Neuropharmacology 27:1249-1256
65. Willetts J, Balster RL (1988b) Phencyclidine-like discriminative stimulus properties of MK-801 in rats. Eur J Pharmacol 146:167-169
66. Witkin JM, Gasior M, Heifets B, Tortella FC (1999) Anticonvulsant efficacy of N-methyl-D-aspartate antagonists against convulsions induced by cocaine. J Pharmacol Exp Ther 289:703-711
67. Ybema CE, Slangen JL, Olivier B, Mos J (1993) Dose-dependent discriminative stimulus properties of 8-OH-DPAT. Behav Pharmacol 4:610-624
68. Zajaczkowski W, Quack G, Danysz W (1996) Infusion of (+)-MK-801 and memantine - contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur J Pharmacol 296:239-246